Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
Peng Liu,Shan-Shan Zhang,Yun Liang,Zi-Jun Gao,Wei Gao,Bu-Huai Dong
DOI: https://doi.org/10.2147/NDT.S388764
IF: 2.989
2022-12-07
Neuropsychiatric Disease and Treatment
Abstract:Peng Liu, 1, 2 Shan-Shan Zhang, 1, 2 Yun Liang, 1, 2 Zi-Jun Gao, 1 Wei Gao, 3 Bu-Huai Dong 1 1 Department of Anesthesiology, Xi'an Honghui Hospital, Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China; 2 Xi'an Medical University, Xi'an, People's Republic of China; 3 Department of Anesthesiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China Correspondence: Bu-Huai Dong, Department of Anesthesiology, Xi'an Honghui Hospital, Affiliated Hospital of Xi'an Jiaotong University, No. 555, Youyi East Road, Nanqimen, Xi'an, 710054, People's Republic of China, Tel +86 29-85260965, Email Objective: To evaluate the efficacy and safety of esketamine + antidepressant in treatment-resistant depression. Methods: We searched PubMed, Web of Science, Embase, CNKI, and Wanfang databases to obtain published information on esketamine + antidepressant from inception to July 2022. We searched for randomized controlled studies on the treatment of depression with a double-blind induction phase. Outcome indicators included changes in Montgomery-Asberg Depression Rating Scale (MADRS) scores before and after treatment, effective response rate, remission rate, and changes in self-rating depression scale (SDS). We analyzed data using Review Manager 5.4 and assessed the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) analysis. Results: A total of seven articles were included, including 701 patients in the esketamine + antidepressant group and 551 in the placebo group. Meta-analysis results showed that esketamine + antidepressant could improve the MADRS score in patients with treatment-resistant depression (MD = − 2.68, 95% CI − 3.98 to − 1.37, P < 0.0001), SDS (MD = − 2.9, 95% CI − 4.01 to − 1.79, P < 0.00001), response rate at the end of the double-blind induction period (RR = 1.28, 95% CI 1.12 to 1.46, P = 0.0002), remission rate at the end of the double-blind induction period (RR = 1.39, 95% CI 1.18 to 1.63, P < 0.0001), Five-Dimensional Health Scale (EQ-5D-5L) (MD = 0.05, 95% CI 0.02 to 0.08, P = 0.00009), Visual Analogue Scale of Health Status (EQ-VAS) (MD = 5.54, 95% CI 2.37 to 8.71, P = 0.0006). Conclusion: Esketamine + antidepressant has an obvious curative effect in treatment-resistant depression and can rapidly improve depression in patients, quality of life and satisfaction, but minor adverse reactions can occur. Keywords: esketamine, treatment-resistant depression, refractory depression, antidepressant, meta-analysis Major depressive disorder is a common mental illness. The prevalence of major depressive disorder varies widely in countries worldwide, but about 6% of cases seriously affect social and psychological functions and reduce the quality of life. The mechanism of action is unclear, 1 but about 10% to 30% of cases are refractory. 2 Treatment-resistant depression is defined as the failure to achieve clinical remission even after receiving a sufficient amount and course of two completely different drugs with good patient compliance. 3,4 Authoritative experts worldwide believe that the direction of depression treatment should be to improve health status, reduce recurrence, and improve quality of life. 5 However, the ineffectiveness of existing clinical therapy prompted the US Food and Drug Administration to approve a new nasal spray antidepressant in 2019, esketamine, for treating adult patients with refractory depression. Due to its special development history (K powder) and mild side effects, it requires strict and standardized use. Esketamine, the S enantiomer of racemic ketamine, belongs to the NMDA receptor blocker. Compared with racemic ketamine, esketamine has less psychomimetic effect, more anesthetic, and analgesic activity, and 3 to 4 times more affinity for NMDA receptors than R-ketamine. 6 The literature has reported that the radioligand-binding properties of NMDA receptors produce region-specific adaptive changes in patients with long-term antidepressant use, 7 suggesting that it may be one of the antidepressant mechanisms. A review reported that esketamine could also activate the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAr), 8 which can regulate multiple signaling pathways of synaptic plasticity; induce brain-derived neurotrophic factor expression; increase the release of monoamine transmitters in the central nervous system; promote angiogenesis and synapse regeneration, and enhance neuronal activity. 9 Despite the growing interest in the treatment of refractory -Abstract Truncated-
psychiatry,clinical neurology